12:00 AM
 | 
Jan 20, 2014
 |  BC Week In Review  |  Company News  |  Deals

Celgene, NantWorks deal

Celgene partnered with the NantBioscience subsidiary of Patrick Soon-Shiong's NantWorks to develop a pipeline of cancer drugs using the nanoparticle albumin-bound (nab) technology Celgene gained in its acquisition of Soon-Shiong's former company, Abraxis Bioscience Inc. The deal includes rights to two...

Read the full 183 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >